Clinical Trial Detail

NCT ID NCT01750918
Title BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

colorectal cancer

Therapies

Fluorouracil

Dabrafenib + Panitumumab

Dabrafenib + Panitumumab + Trametinib

Panitumumab + Trametinib

Age Groups: adult senior

Additional content available in CKB BOOST